Xie Yang, Wang Jiajia, Li Suyun, Fu Lili, Sun Jie, Zhao Jinling, Zhang Huaru, Jia Kui, Zhao Qingxia, Li Bin, Li Jiansheng
Department of Respiratory Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan, China.
Co-construction Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan and Education Ministry of P. R. China/Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou 450046, Henan, China.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Aug;32(8):922-927. doi: 10.3760/cma.j.cn121430-20200528-00485.
To evaluate the clinical effect of integrated traditional Chinese and Western medicine on common type of coronavirus disease 2019 (COVID-19) in Henan Province.
A prospective single arm clinical study was performed. Patients with common type of COVID-19 admitted to seven designated hospitals for COVID-19 in Henan Province from January 25th to February 26th, 2020 were enrolled, and treated with integrated traditional Chinese and Western medicine. The negative transformation of 2019 novel coronavirus (2019-nCoV) nucleic acid, disease outcome, hospital stay, clinical symptoms and signs scores, and chest imaging performance were observed.
Totally 86 cases were included in the analysis, including 48 males (55.8%), aged 43.5 (35.0, 53.3) years old, 24 patients (27.9%) with previous medical history. Fifty-eight patients were primarily diagnosed COVID-19 and 28 patients were transferred. The 2019-nCoV nucleic acid of 86 cases (100%) turned negative, and the median time of turning negative was 10 (7, 14) days. Eighty-six cases (100%) were discharged from hospital, and none turned into the severe type; the average length of hospital stay was (13.8±5.6) days. The scores of fever, cough, chest tightness, shortness of breath, and fatigue decreased with the treatment time, and the scores of 7 days and 14 days after treatment were significantly lower than those before treatment [fever (points): 0 (0, 0), 0 (0, 0) vs. 1 (0, 1); cough (points): 1 (0, 1), 0 (0, 1) vs. 1 (0, 2); chest tightness (points): 0 (0, 0), 0 (0, 0) vs. 0 (0, 1); shortness of breath (points): 0 (0, 0), 0 (0, 0) vs. 0 (0, 1); fatigue (points): 0 (0, 1), 0 (0, 1) vs. 1 (0, 1); all P < 0.05]. The improvement rate of X ray and CT image was 42.9% (12/28) and 81.0% (64/79), respectively.
The treatment with integrated traditional Chinese and Western medicine has good curative effect on common type of COVID-19 in 7 designated hospitals of Henan Province. It can improve the clinical symptoms, promote the absorption of pulmonary inflammation, and to some extent control the progress of disease and shorten the time of turning negative of virus nucleic acid and hospital stay.
评价中西医结合治疗河南省普通型新型冠状病毒肺炎(COVID-19)的临床疗效。
进行一项前瞻性单臂临床研究。纳入2020年1月25日至2月26日在河南省7家新冠肺炎定点医院收治的普通型COVID-19患者,采用中西医结合治疗。观察新型冠状病毒(2019-nCoV)核酸转阴情况、疾病转归、住院时间、临床症状和体征评分以及胸部影像学表现。
共纳入86例患者进行分析,其中男性48例(55.8%),年龄43.5(35.0,53.3)岁,有既往病史者24例(27.9%)。初诊COVID-19患者58例,转院患者28例。86例患者(100%)的2019-nCoV核酸转阴,转阴中位时间为10(7,14)天。86例患者(100%)出院,无1例转为重型;平均住院时间为(13.8±5.6)天。发热、咳嗽、胸闷、气短、乏力评分随治疗时间延长而降低,治疗7天和14天后评分显著低于治疗前[发热(分):0(0,0),0(0,0)对比1(0,1);咳嗽(分):1(0,1),0(0,1)对比1(0,2);胸闷(分):0(0,0),0(0,0)对比0(0,1);气短(分):0(0,0),0(0,0)对比0(0,1);乏力(分):0(0,1),0(0,1)对比1(0,1);均P<0.05]。X线和CT影像改善率分别为42.9%(12/28)和81.0%(64/79)。
中西医结合治疗对河南省7家定点医院的普通型COVID-19有良好疗效。可改善临床症状,促进肺部炎症吸收,在一定程度上控制疾病进展,缩短病毒核酸转阴时间和住院时间。